Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.59 |
| ▸ | QDPR | P09417 | 1/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 14/20 | 0.57 |
| ▸ | ESR1 | P03372 | 9/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | ESRRB | O95718 | 2/20 | 0.51 |
| ▸ | ESRRG | P62508 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654282 | 0.98 | QDPR (0.62) | QDPRSLC18A3SIGMAR1ESR2ESR1 | |
| Hydrochloric Acid SCHEMBL2271784 | 0.96 | QDPR (0.60) | QDPRSLC18A3SIGMAR1ESR2ESR1 | |
| Ethane SCHEMBL28134207 | 0.94 | ESR2 (0.59) | QDPRSLC18A3SIGMAR1ESR2ESR1 | |
| SCHEMBL25936803 | 0.90 | ESR2 (0.55) | QDPRSLC18A3SIGMAR1ESR2ESR1 | |
| SCHEMBL20805968 | 0.85 | HTR3A (0.66) | QDPRESR2 | |
| SCHEMBL1865798 | 0.81 | ESR2 (0.81) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL1986271 | 0.81 | ESR2 (0.81) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL3811445 | 0.81 | ESR2 (0.81) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL3809909 | 0.81 | ESR2 (0.81) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL4676148 | 0.79 | SLC18A3 (0.67) | QDPRSLC18A3SIGMAR1ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025120168-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CRYPTOSPORIDIUM INFECTIONS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) | 2025-06-12 | — | — | WO | disclosed |
| US-20250018046-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. | 2025-01-16 | — | — | US | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| CN-118574821-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4366834-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA UK LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| CN-106536524-B | For [1,2,4] triazol [4,3-B] pyridazine used in the treatment in proliferative diseases | 阿斯利康(瑞典)有限公司 | 2019-11-15 | — | — | CN | disclosed |
| US-10407432-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-9944650-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2018-04-17 | — | — | US | disclosed |
| EP-3174881-B1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | disclosed |
| EP-3174881-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | Astrazeneca AB (SE) | 2017-06-07 | — | — | EP | disclosed |
| CN-106536524-A | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | 阿斯利康(瑞典)有限公司 | 2017-03-22 | — | — | CN | disclosed |
| WO-2016016618-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407432-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | SIGMAR1 2764/4885QDPR 953/4885SLC18A3 4860/4885 |
| US-20250018046-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | SIGMAR1 4185/4885QDPR 3773/4885SLC18A3 4737/4885 |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, CCNB2 | SIGMAR1 2764/4885QDPR 953/4885SLC18A3 4860/4885 |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNI, CCNB1 | SIGMAR1 2463/4885QDPR 1072/4885SLC18A3 4859/4885 |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | SIGMAR1 4448/4885QDPR 1334/4885SLC18A3 4732/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | SIGMAR1 4103/4885QDPR 3033/4885SLC18A3 4705/4885 |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | SIGMAR1 2764/4885QDPR 953/4885SLC18A3 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.